One of our members has shared this information which she thought might be of interest to some of our members.
A group of people with MS are gathering real-world experiences from people who have been switched from Tysabri IV (originator natalizumab) to Tyruko (biosimilar natalizumab) within the NHS.
This survey aims to better understand how this transition has affected patients—not just in terms of relapse control, but overall quality of life—and to present these findings directly to the NHS.
They want to know;
- Whether patients received clear information and discussion about biosimilars before the switch
- The level of patient involvement in decision-making and consent
- The support provided during the transition period
- Any changes or impacts on symptoms, wellbeing, and daily life
- The quality and adequacy of ongoing healthcare support
You can fill out the survey here
And find out more here on change.org
